SYK vs BSX stock comparison
Stryker vs. Boston Scientific · data as of November 13, 2026
Stryker (SYK) has a market value of about $117.9B, Boston Scientific (BSX) about $64.3B. Over their latest twelve months Stryker had revenue of $26.3B and Boston Scientific $21.1B.
On our five checks Boston Scientific scores higher: 3.0 out of 5 (average) against 2.8 (average).
By area, the stronger company is Boston Scientific on value; Boston Scientific on future growth; Stryker on track record; Boston Scientific on financial health; Stryker on shareholder returns.
Boston Scientific is cheaper on earnings (P/E 18.8 vs. 33.0).
Stryker leads on 8 of the compared lines and Boston Scientific on 15.
Side by side
| SYK | BSX | |
|---|---|---|
| Size and price | ||
| Market cap | $117.9B | $64.3B |
| Share price | $309.64 | $44.34 |
| Score | ||
| Overall score (of 5) | 2.8 | 3.0 |
| Value | 0 | 3 |
| Future growth | 4 | 5 |
| Track record | 3 | 2 |
| Financial health | 3 | 4 |
| Shareholder returns | 4 | 1 |
| Valuation | ||
| P/E (TTM) | 33.0 | 18.8 |
| Forward P/E | 18.9 | 14.4 |
| Price / free cash flow | 25.8 | 19.3 |
| Price / sales | 4.5 | 3.1 |
| EV / EBITDA | 18.5 | 14.1 |
| PEG | 2.22 | — |
| DCF value vs. price | −38% | −58% |
| Business | ||
| Revenue | $26.3B | $21.1B |
| Net income | $3.6B | $3.5B |
| Free cash flow | $4.6B | $3.3B |
| Net margin | 13.8% | 16.6% |
| Gross margin (5-yr avg.) | 63.7% | 68.9% |
| ROIC (5-yr avg.) | 9.0% | 5.9% |
| Growth | ||
| Revenue growth (1 yr) | 11.2% | 19.9% |
| Revenue growth (5 yrs, per year) | 11.8% | 15.2% |
| EPS growth (5 yrs, per year) | 14.9% | — |
| Balance sheet and payouts | ||
| Net cash (cash minus debt) | -$12.2B | -$11.3B |
| Dividend yield | 1.14% | None |
| Shareholder yield | 1.1% | 0.0% |
| Analysts | ||
| Upside to average target | +10% | +12% |
| Consensus rating | Buy | Buy |
Highlighted = the better figure on that line. Revenue, net income and free cash flow: SYK TTM to September 30, 2026, BSX TTM to September 30, 2026. Not investment advice.
Frequently asked questions
Which is the better stock, Stryker or Boston Scientific?
We do not give buy or sell advice. On our five checks (value, growth, track record, financial health and shareholder returns) Boston Scientific scores 3.0 out of 5 and Stryker 2.8; the table shows where each one is stronger.
Is Stryker cheaper than Boston Scientific?
On trailing earnings, Boston Scientific trades at a P/E of 18.8 and Stryker at 33.0, so Boston Scientific is cheaper by this measure. A lower P/E can also reflect slower expected growth.
Which grows faster, Stryker or Boston Scientific?
Over five years Boston Scientific grew revenue about 15.2% a year and Stryker about 11.8% a year.
Which pays a higher dividend?
Stryker yields 1.14% and Boston Scientific nothing (no dividend).
Full Stryker analysis → Full Boston Scientific analysis →
More comparisons
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.